Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Medicines on shelf - Prasanth - stock.adobe.com.jpg
Rising Costs of Biologics for Plaque Psoriasis Highlight Savings Potential

April 24th 2025

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial

April 10th 2025

Psoriasis oral treatment | Image credit: Pawel - stock.adobe.com
Women Have Lower Drug Survival With Biologics for Psoriasis, Including IL-17 and IL-23 Inhibitors

April 7th 2025

Psoriasis treatment concept | Sviatlana - stock.adobe.com
Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity

April 1st 2025

Bimekizumab | Image credit: luchschenF - stock.adobe.com
Bimekizumab Reduces Inflammation, Cardiovascular Risk

March 21st 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
April 25th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
April 25th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Valuable Quality of Life Assessments in Psoriasis
January 31st 2023

Valuable Quality of Life Assessments in Psoriasis

Amy McMichael, MD, explores why psoriasis can substantially affect quality of life more severely in some ethnicities more than others.
Improving Treatment for Psoriasis Across All Skin Phenotypes
January 24th 2023

Improving Treatment for Psoriasis Across All Skin Phenotypes

Bruce Sherman, MD, FCCP, FACOEM, explores how to improve treatment for psoriasis and education surrounding diagnosing psoriasis for all skin phototypes.
Factors to Evaluate When Initiating Psoriasis Treatment
January 24th 2023

Factors to Evaluate When Initiating Psoriasis Treatment

Amy McMichael, MD, and Maria Lopes, MD, MS, review factors to evaluate when starting treatment and how to educate patients on the possible adverse events from that treatment.
Wildfire in forest.
January 22nd 2023

Wildfire Air Pollution Linked With Increased Rates of Psoriasis Clinic Visits Among Adults

Matthew Gavidia
After a delayed lag period, air pollution from a wildfire was associated with modestly increased rates of clinic visits for psoriasis among adults starting 5 weeks after the fire and peaking at 8 to 9 weeks after the fire.
Image of Air Pollution
January 17th 2023

Potential Link Found Between Spikes in Air Pollution, Outpatient Psoriasis Visits

Jared Kaltwasser
Female patients and people younger than 18 years were particularly sensitive to pollution levels, this study found.
Biologic injectable drug.
January 13th 2023

Examining Patient Preferences for Biologic Use in Psoriasis

Matthew Gavidia
Following COVID-19–related lockdown measures, preferences for the use of biologics among Japanese patients with psoriasis addressed administration route, visits, and risk of serious infections requiring hospitalization, with some differences observed between specific subgroups.
person working.
January 5th 2023

Improved Work-, Study-Related Productivity Shown With Tildrakizumab in Patients With Psoriasis

Matthew Gavidia
Abstract findings presented at the 2022 American Academy of Dermatology Annual Meeting showed that patients with moderate to severe psoriasis achieved improvement in work-/study-related productivity with tildakizumab vs placebo after only 2 doses.
patient with psoriasis flare.
January 5th 2023

Examining Modifiable Risk Factors in Psoriasis

Matthew Gavidia
Findings of a Mendelian randomization analysis showed that greater body mass index as a child and adult and incidence of smoking were associated with an increased risk of psoriasis, whereas having more education was cited as a potential protective factor against development.
People walking.
January 3rd 2023

Systemic Drug Trends Seemingly Vary by Season in Patients With Psoriasis

Matthew Gavidia
Approximately 14,280 more US patients with psoriasis were estimated to initiate a biologic in Spring than in other seasons, and over 840 more biologic users switched in Spring than in Winter.
image with the language "The Top 5 Psoriasis Content of 2022"
December 26th 2022

Top 5 Most-Popular Psoriasis Content of 2022

Pearl Steinzor
This year’s most-popular content on psoriasis include research regarding disparities and socioeconomic factors that impact psoriasis treatment and an interview on shared decision making.
Health Inequities Impacting Optimal Treatment for Patients With Psoriasis
December 23rd 2022

Health Inequities Impacting Optimal Treatment for Patients With Psoriasis

Bruce Sherman, MD, FCCP, FACOEM, underlines the impact of health inequities for patients diagnosed with psoriasis.
The Benefits and Limitations of the PASI Score
December 23rd 2022

The Benefits and Limitations of the PASI Score

Maria Lopes, MD, MS, provides an overview of the PASI scoring system.
The Impact of Psoriasis on the Quality of Life
December 23rd 2022

The Impact of Psoriasis on the Quality of Life

Amy McMichael, MD, discusses the impact of psoriasis on a patient’s quality of life.
Prevalence and Incidence of Psoriasis
December 23rd 2022

Prevalence and Incidence of Psoriasis

Ryan Haumschild, PharmD, MS, MBA, leads a panel discussion highlighting the current prevalence of psoriasis.
imflammatory arthritis
December 20th 2022

UK Diagnoses of Rheumatological Conditions Decreased During the Pandemic

Justina Petrullo
Diagnoses of psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, or undifferentiated inflammatory arthritis saw a dramatic decline during the early stages of the COVID-19 pandemic.
graphic of the brain
December 15th 2022

How Can Psoriasis, Depression Impact the Brain?

Giuliana Grossi
An immune-mediated relationship between the brain and skin has been hypothesized in previous studies about psoriasis.
Image of a sad child
December 6th 2022

Children With Psoriasis Should Be Screened for Mental Health Conditions, Say Researchers

Jaime Rosenberg
A review of available literature, although limited, has pointed to a link between pediatric psoriasis and anxiety and depression. Previous research has made a clear association between psoriasis and mood disorders in adults.
Psoriasis
December 3rd 2022

Researchers Find No Tumor Recurrence, Progression in Patients Receiving Biologic for Psoriasis

Jaime Rosenberg
Data on the use of biologics for psoriasis among patients with a history of cancer have remained sparse. However, new findings provide the largest amount of real-world data on the use of the biologic secukinumab in these patients.
Patient having a virtual doctor's visit
November 19th 2022

Virtual Assistants in Teledermatology May Improve Quality of Life for Patients With Psoriasis

Rose McNulty
A prospective study found that patients and providers saw benefits while using a virtual assistant integrated into a teledermatology program.
Stamp of Approval image
November 18th 2022

Patients With Psoriasis Prescribed Biologics Face Care Delays From Prior Authorization

Rose McNulty
A brief report found that a need for prior authorization affected biologic approval wait times for patients with psoriasis, especially those with private insurance.
graphic depicting science
October 31st 2022

Emerging Treatments Could Add to Targeted Options for Psoriasis, PsA

Jaime Rosenberg
Emerging therapies for psoriasis and psoriatic arthritis (PsA) include treatments that target interleukin (IL)-23 and IL-17, which could lead to the approval of new IL-23 and IL-17 inhibitors, as well as expanding the use of currently approved options.
image of different skin colors
October 20th 2022

Cost, Structural Barriers Limit Equal Access to Health Care in Inflammatory Skin Disease

Pearl Steinzor
Black and Hispanic patients living with chronic inflammatory skin disease (CISD) have more barriers to care compared with White patients with CISD, according to a recent study.
Hand with psoriasis
October 19th 2022

Pruritus Lowers Quality of Life, Sleep Quality in Patients With Psoriasis

Julia Bonavitacola
Quality of life and sleep quality were both negatively impacted by pruritus when it occurs with psoriasis, according to a recent study.
closeup of psoriasis
October 18th 2022

Level of QOL Impact of Psoriasis Does Not Appear to Be Influenced by Affected Body Region

Jaime Rosenberg
Prior to the analysis, researchers hypothesized that having localized psoriasis on more visible and/or more sensitive areas, including the face and genitals, would yield a more significant impact on quality of life.
Doctor giving advice to patients
October 11th 2022

Researchers Explore Similarities, Differences in Guidelines for PsA Treatment

Jaime Rosenberg
In the last 2 years, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) have updated their recommendations to integrate guidance for new treatment options.
Image of medical data review
October 5th 2022

Does Early Intervention Promote Favorable, Sustained Outcomes in Psoriasis?

Jaime Rosenberg
The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.
Patrick Burnett, MD, PhD, FAAD.
September 17th 2022

Dr Patrick Burnett on Shared Decision-Making for Moderate to Severe Psoriasis

Matthew Gavidia
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses clinical recommendations for patients with moderate to severe psoriasis, particularly the need for shared decision-making.
Picture of 3 globes
September 13th 2022

Study Highlights Wide Variation in Mortality of Spondyloarthritis, IBD Across the Globe

Jaime Rosenberg
The study also found that over a decade, death rates did not change significantly for ankylosing spondylitis but decreased for inflammatory bowel disease (IBD).
Patrick Burnett, MD.
September 10th 2022

Dr Patrick Burnett Discusses Efficacy, Safety Profile of Roflumilast Cream in Psoriasis

Matthew Gavidia
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks on the positive safety and efficacy profile shown in the DERMIS-1 and DERMIS-2 trials exploring use of roflumilast cream in patients with chronic plaque psoriasis, including those with intertriginous disease.
picture of finger
September 9th 2022

Researchers Outline Treatment Options for Nail Psoriasis, Other Common Nail Disorders

Jaime Rosenberg
Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.
<123456789
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo